Skip to main content

Lipid metabolism disorders in diabetes

Editors:
Andrea Baragetti, PhD, University of Milan, Italy
Giuseppina Russo, MD, PhD, University of Messina, Italy

Submission Status: Open   |   Submission Deadline: 30 April 2024


Diabetology & Metabolic Syndrome is calling for submissions to our collection on Lipid metabolism disorders in diabetes. Disorders in lipid metabolism refer to excessive synthesis or defective catabolism of large triglycerides and cholesterol enriched lipoprotein (namely, very low-density lipoproteins (VLDL)), and are exacerbated by very prevalent risk factors for diabetes and metabolic disorders, including adherence to hypercaloric fats-enriched diets and/or physical inactivity. On the long-term, these disorders lead to the accumulation of the cholesterol enriched, low-density lipoproteins (LDL) and to a reduced availability of the so called “high-density lipoproteins” (HDL), generating a dangerous combination that accelerates atherosclerosis, macro- and micro-angiopathies, and dramatically enhances the risk of cardiovascular mortality in diabetes.

Image credit: Andrea Baragetti

About the collection

Diabetology & Metabolic Syndrome is calling for submissions to our collection on Lipid metabolism disorders in diabetes. Disorders in lipid metabolism refer to excessive synthesis or defective catabolism of large triglycerides and cholesterol enriched lipoprotein (namely, very low-density lipoproteins (VLDL)), and are exacerbated by very prevalent risk factors for diabetes and metabolic disorders, including adherence to hypercaloric fats-enriched diets and/or physical inactivity. On the long-term, these disorders lead to the accumulation of the cholesterol enriched, low-density lipoproteins (LDL) and to a reduced availability of the so called “high-density lipoproteins” (HDL), generating a dangerous combination that accelerates atherosclerosis, macro- and micro-angiopathies, and dramatically enhances the risk of cardiovascular mortality in diabetes.

Furthermore, disorders in lipid metabolism are not only strictly connected to the even more complex mechanisms of insulin resistance and ectopic visceral adiposity, but they are also hardwired with derailments in inflammatory pathways and in an unfavorable reprogramming of the innate/adaptive immune responses. This pathophysiological link further complicates the prognosis and accelerate the development of additional systemic co-morbidities at different organ level, where high risk of infections, amputations, neuropathies, cognitive impairments/depression are only some examples.

Pharmacological research produced important solutions in the treatment of lipid disorders to constrain the metabolic burden leading to premature mortality in diabetes, although preventive approaches and novel therapeutics perspectives focusing on inflammation and co-morbidities are still far from being optimal.

Therefore, by including novel research (either as basic science or clinically oriented) and reviews (either as systematic or narrative reviews), this collection of articles in Diabetology and Metabolic Syndrome aims at contributing to strengthen the vision of lipid metabolism disorders as a cornerstone for the systemic and multi-organ consequences in diabetes. We believe that this purpose will be of interest for both researchers, broadening the understanding of novel cellular and molecular aspects, and for healthcare professionals, being sensitized toward timely and effective preventive approaches.

Suggestions for possible topics could include:

•    Triglycerides; cholesterol; VLDL; LDL; HDL

•    Preventive approaches; diet and physical exercise

•    Adiposity

•    Co-morbidites of diabetes; neuropathies; cognitive impairments and mood.

•    Inflammation; innate and/or adaptive responses to lipids

•    Novel biomarkers

•    “Omics” to study lipid metabolism disorders

•    Genetic studies

•    Pharmacological perspectives

  1. To evaluate the effect of intrahepatic cholestasis of pregnancy (ICP) with gestational diabetes mellitus (GDM) on perinatal outcomes and establish a prediction model of adverse perinatal outcomes in women with...

    Authors: Xia Li, Qin-Yu Cai, Xin Luo, Yong-Heng Wang, Li-Zhen Shao, Shu-Juan Luo, Lan Wang, Ying-Xiong Wang, Xia Lan and Tai-Hang Liu
    Citation: Diabetology & Metabolic Syndrome 2024 16:57
  2. Unhealthy dietary habits and highly caloric foods induce metabolic alterations and promote the development of the inflammatory consequences of obesity, insulin resistance, diabetes and cardiovascular diseases....

    Authors: Elisa Mattavelli, Elisa Piperni, Francesco Asnicar, Laura Redaelli, Liliana Grigore, Fabio Pellegatta, Amir Nabinejad, Sabrina Tamburini, Nicola Segata, Alberico Luigi Catapano and Andrea Baragetti
    Citation: Diabetology & Metabolic Syndrome 2024 16:50
  3. Diabetic nephropathy (DN), one of the more prevalent microvascular complications in patients diagnosed with diabetes mellitus, is attributed as the main cause of end-stage renal disease (ESRD). Lipotoxicity in...

    Authors: Jingshu Sun, Xinyu Zhang, Simeng Wang, Dandan Chen, Jianqiang Shu, Nannan Chong, Qinglian Wang and Ying Xu
    Citation: Diabetology & Metabolic Syndrome 2024 16:38
  4. Abnormalities in glucose and lipid metabolism contribute to the progression and exacerbation of type 2 diabetes mellitus (T2DM). Fish oil and probiotics are dietary supplements that have the potential to impro...

    Authors: Mei Zhang, Fan Yang, Qiu Feng, Yanghong Ou, Jiaxing Zhang, Haiyan Wan, Hongyi Cao and Peng Ning
    Citation: Diabetology & Metabolic Syndrome 2024 16:25
  5. Inflammatory bowel disease (IBD) has been associated with lipid-lowering drugs in observational studies. Drug-target Mendelian randomization (MR) was utilized in this study to examine the causal relationship b...

    Authors: Jiaxi Zhao, Rong Chen, Mengqi Luo, Hongping Gong, Kaixin Li and Qian Zhao
    Citation: Diabetology & Metabolic Syndrome 2024 16:12
  6. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is considered a new biomarker for atherosclerosis, but its ability to predict cardiovascular outcomes has been controversial. This study aimed to address t...

    Authors: Juan Huang, Jun-Xu Gu, Kun Wang, Ai-Min Zhang, Ting-Ting Hong, Shan-Shan Li, Xiao-Qin Yao, Ming Yang, Yue Yin, Na Zhang, Ming Su, Jia-Jia Hu, Xue-Zhi Zhang and Mei Jia
    Citation: Diabetology & Metabolic Syndrome 2023 15:260
  7. Insulin resistance is linked to atherosclerotic cardiovascular diseases and stroke, whereas less is known about adipose tissue specific insulin resistance and outcomes after ischemic stroke. This study aimed t...

    Authors: Qi Zhou, Hongyi Yan, Aoming Jin, Xia Meng, Jinxi Lin, Hao Li, Yongjun Wang and Yuesong Pan
    Citation: Diabetology & Metabolic Syndrome 2023 15:246
  8. Cardiometabolic multi-morbidity (CMM) is emerging as a global healthcare challenge and a pressing public health concern worldwide. Previous studies have principally focused on identifying risk factors for indi...

    Authors: Zenglei Zhang, Lin Zhao, Yiting Lu, Xu Meng and Xianliang Zhou
    Citation: Diabetology & Metabolic Syndrome 2023 15:226
  9. Diabetic retinopathy (DR) is a common complication of DM and may go unnoticed until irreversible damage occurs. Its screening can contribute to the early detection. Although, there are no studies which investi...

    Authors: Levimar Rocha Araújo, Juliana Lambert Orefice, Monica Aramuni Gonçalves, Nathalia Sernizon Guimarães, Aleida Nazareth Soares, Tassila Salomon and Alessandra Hubner de Souza
    Citation: Diabetology & Metabolic Syndrome 2023 15:225
  10. Glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 are the main incretin hormones, and be responsible for the insulinotropic incretin effect. The addition of a GIP agonist to a GLP-1agonist has been ...

    Authors: Qian Zhou, Xingxing Lei, Shunlian Fu, Pan Liu, Cong Long, Yanmei Wang, Zinan Li, Qian Xie and Qiu Chen
    Citation: Diabetology & Metabolic Syndrome 2023 15:222
  11. Physical exercise is the first-line intervention for prediabetes, and metformin is the most widely used oral insulin-sensitizing agent. Moreover, intermuscular adipose tissue (IMAT) directly affects insulin re...

    Authors: Fuyao Yu, Chuan Xing, Yiping Fan, Yanping Liu, Peng Su, Qiuhua Yang, Yanbin Dong, Yang Hou and Shinong Pan
    Citation: Diabetology & Metabolic Syndrome 2023 15:221
  12. Age is a major risk factor associated with the complexity of coronary artery disease (CAD), and the prognosis of elderly patients with coronary heart disease is relatively poor. Metabolic disturbances are prev...

    Authors: Xiaona wang, Xinqiang Ji, Jianhui yu and Fan wang
    Citation: Diabetology & Metabolic Syndrome 2023 15:176
  13. Metabolomic signatures of type 2 diabetes mellitus (T2DM) in Tibetan Chinese population, a group with high diabetes burden, remain largely unclear. Identifying the serum metabolite profile of Tibetan T2DM (T-T...

    Authors: Jinli Meng, Fangfang Huang, Jing Shi, Chenghui Zhang, Li Feng, Suyuan Wang, Hengyan Li, Yongyue Guo, Xin Hu, Xiaomei Li, Wanlin He, Jian Cheng and Yunhong Wu
    Citation: Diabetology & Metabolic Syndrome 2023 15:146
  14. Recently, metabolic dysfunction-associated fatty liver disease (MAFLD) has been proposed to replace non-alcoholic fatty liver disease (NAFLD) to emphasize the pathogenic association between fatty liver disease...

    Authors: Zhihao Wei, Zhe Huang, Zongshuang Song, Wenliu Zhao, Dandan Zhao, Yizhen Tan, Shuohua Chen, Peng Yang, Yun Li and Shouling Wu
    Citation: Diabetology & Metabolic Syndrome 2023 15:137
  15. The Triglyceride and Glucose (TyG) index has been found to have a strong correlation with the recurrence of acute ischemic stroke (AIS) and poor patient outcomes. Nevertheless, the relationship between the TyG...

    Authors: Jia Wang, Hao Tang, Xiaokun Wang, Jiarong Wu, Jiaqi Gao, Shuang Diao and Yun Wu
    Citation: Diabetology & Metabolic Syndrome 2023 15:112

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles, Data Notes, Case Reports, Study Protocols, and Database Articles. Before submitting your manuscript, please ensure you have read our submission guidelines. Articles for this Collection should be submitted via our submission system, Snapp. During the submission process you will be asked whether you are submitting to a collection, please select "Lipid metabolism disorders in diabetes" from the dropdown menu.

Articles will undergo the journal’s standard peer-review process and are subject to all of the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer review process. The peer review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.